Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Ali Zarrinpar, M.D., Ph.D.
Ali Zarrinpar, M.D., Ph.D.

Specialty:

Hepatobiliary Surgery
Transplantation Surgery
General Surgery

General Information:

Gender:
Male
Language(s):
English, Farsi

Affiliation(s):

Assistant Professor, Department of Surgery, Division of Liver and Pancreas Transplantation
Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica

Education:

Fellowship:
Multiorgan Transplantation and Hepatobiliary Surgery, UCLA School of Medicine, 2010-2012
Residency:
General Surgery, UCLA School of Medicine, 2006 - 2010
Internship:
General Surgery, UCLA School of Medicine, 2005 - 2006
Medical Degree:
M.D., UCSF School of Medicine, 2005
Degree:
Ph.D., UCSF, 2003

Certification(s):

Medical Board Certification(s):
Surgery, American Board of Surgery, 2011

Contact Information:

Phone:
(310) 794-7788 Patient appointments
(310) 206-3748 Referring physician
Email:

Practice Information:

Clinical Interest(s):
Hepatobiliary
Liver Cancer
Liver Transplantation

Scientific Interest(s):

Dr. Ali Zarrinpar’s research focuses on the understanding and treatment of hepatocellular carcinoma (HCC), the fifth most common type of cancer, at both a clinical and basic level. His lab is working to derive prognostic scoring models for survival after liver transplantation for liver cancer, using pre-transplant data from recipients. Seeking to improve upon current criteria used to determine which patients are eligible for liver transplantation, Zarrinpar’s lab is looking to discover better markers of survival using lab results and response to neoadjuvant treatment.

On a basic science level, Zarrinpar’s research is of dual focus. First is to determine the genetic and molecular fingerprint of HCC, as it is a crucial component to understanding the initiation and aggressiveness of this tumor. His lab hopes to identify the molecular signature of HCC as distinct from cirrhosis by linking array data with clinical prognosis and outcomes, and evaluating key signaling pathways as markers of earlier disease and targets for therapy. More specifically, he is exploring the role of lipid metabolism and inflammation in liver carcinogenesis.

Second, Zarrinpar’s lab is investigating Ischemia/reperfusion, which has been shown to promote cancer cell engraftment and growth, and its prevention, which is also a key factor in minimizing cancer recurrence. His lab is further exploring the role of IR injury and inflammation, its prevention and what effect it may have on the recurrence of HCC.

Selected Cancer-Related Publications:

Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013 Jul;10(7):434-40. doi: 10.1038/nrgastro.2013.88. Epub 2013 Jun 11.

Zarrinpar A, Busuttil RW. Liver transplantation: Toward a unified allocation system. Nat Rev Gastroenterol Hepatol. 2011 Oct 5;8(10):542-3. doi: 10.1038/nrgastro.2011.163.

Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):234-42.

Zarrinpar A, Yeh MW. Functional cortical neoplasms. Cancer Treat Res. 2010;153:163-86. doi: 10.1007/978-1-4419-0857-5_10.